

## PERSONAL INFORMATION

**Marta Brambilla**

## POSITION

**05/11/2020 – today****Medical Oncologist, Department of Medical Oncology**Foundation IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy  
Thoracic Cancer Unit

## WORK EXPERIENCE

**05/11/2020 – today****Medical Oncologist, Department of Medical Oncology**Foundation IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy  
Thoracic Cancer Unit**01/11/2017 – 04/11/2020****Specialist registrar, Department of Medical Oncology**Foundation IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy  
Thoracic Cancer Unit, Gastro-Intestinal Cancer Unit, Breast cancer Unit, Melanoma Unit**Specialist registrar, Department of Medical Oncology****01/11/2015 – 31/10/2017**

Santa Maria della Misericordia Hospital and University of Perugia, Italy

Thoracic Cancer Unit, Internal Medicine ward

## EDUCATION AND TRAINING

**01/05/2023 – today****PhD student in Molecular Immunology and Translational Medicine**

The Open University – Milton Keynes, UK

**01/04/2022 – 29/03/2023****Master II level: Methods and Data Analysis in BIOMEDICAL RESEARCH (MEDAL)**

University of Milan-Bicocca

**15/02/2021 – 13/04/2021****Advanced course in clinical research**

Systematic reviews and meta-analysis

**01/11/2017 – 04/11/2020****Medical Oncologist, Department of Medical Oncology**

Degree in Medical Oncology (70/70 cum laude)

Thesis Title: Circulating and tumor associated neutrophil subtypes in hyperprogressive disease upon immune checkpoint inhibitors in advanced non-small cell lung cancer patients.

Foundation IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy

Thoracic Cancer Unit, Gastro-Intestinal Cancer Unit, Breast cancer Unit, Melanoma Unit

**01/11/2015 – 31/10/2017****Specialist registrar, Department of Medical Oncology**

Santa Maria della Misericordia Hospital and University of Perugia, Italy

Thoracic Cancer Unit, Internal Medicine ward

**22/07/2015****Member of Italian Medical Association**

Ordine dei medici e degli odontoiatri di Monza e Brianza, n°03967

**September 2008 – March 2015**

**Bachelor in Medicine and Surgery**

First Class Degree (108/110)

Thesis Title: Phase II clinical trial with Temozolomide in metastatic colorectal cancer selected according to *MGMT* gene silencing.

University of Milano-Bicocca, Faculty of Medicine and Surgery, Monza, Italy

**December 2013 – March 2015**

**Internship in Oncology**

Division of Oncology, Niguarda Ca' Granda Hospital, Milano, Italy

**October 2012**

**Internship in Oncology**

Division of Oncology, San Gerardo Hospital, Monza, Italy

**July 2012**

**Internship in Clinical Research**

Division of Clinical Research, San Gerardo Hospital, Monza, Italy

**September 2003– June 2008**

**Secondary School Diploma**

High School of Science Antonio Banfi, Vimercate, Monza e Brianza, Italy

SCIENTIFIC AFFILIATIONS

**August 2019 – today**

**Member of FONICAP**

ID number 000174

**November 2017 – today**

**Member of ESMO**

ID number 409688

**November 2017 – today**

**Member of AIOM**

**22/07/2015**

**Member of Italian Medical Association**

Medical Association of Monza and Brianza, ID number 03967

**09/07/2015**

**Board certified in Medicine and Surgery**

PERSONAL SKILLS

**Mother tongue(s)**

Italian

**Other language(s)**

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1	C1	B2	B2	B2
French	A2	A2	A2	A2	A2

**Communication skills**

Good communication and presentation skills gained through my scholastic experiences.

Excellent managerial skills gained through my experience of supervisor of Young Component of Red Cross Organization of Monza division.

**Organizational / managerial skills**

Excellent organizational skills gained through the activity of planning fund-raising campaign and promoting events as a referent member of Young Component of Red Cross Organization of Monza division.

**Digital competence**

SELF-ASSESSMENT				
Information processing	Communication	Content creation	Safety	Problem solving
Independent User	Independent user	Independent user	Independent user	Basic user

Microsoft Windows and Mac OS X Operative Systems. Microsoft Office Suite, in particular Word, Excel and Powerpoint. Good ability of data management and statistical analyses with R. Good ability using Internet both as a tool of communication and to search scientific information. Use of Medline database, e.g. Pubmed.

**Driving licence**

B

SCIENTIFIC INVOLVMENT

**ORCID**

<https://orcid.org/0000-0003-1148-7056>

**Publications**

Passiglia F, Lucia Reale M, Lo Russo G, Pasello G, Minuti G, Bulotta A, Galetta D, Pelizzari G, Sini C, Bria E, Roca E, Pilotto S, Genova C, Metro G, Citarella F, Chiari R, Cortinovis D, Delmonte A, Russo A, Tiseo M, Cerea G, Carta A, Scotti V, Vavalà T, Brambilla M, Buffoni L, Buosi R, Catania C, Gori S, Grisanti S, Agustoni F, Garbo E, Malapelle U, Novello S. Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program. *Lung Cancer*. 2024 Jan;187:107444. doi: 10.1016/j.lungcan.2023.107444. Epub 2023 Dec 15. PMID: 38157806.

Marinelli D, Gallina FT, Pannunzio S, Di Civita MA, Torchia A, Giusti R, Gelibter AJ, Roberto M, Verrico M, Melis E, Tajè R, Cecere FL, Landi L, Nisticò P, Porciello N, Occhipinti M, Brambilla M, Forde PM, Liu SV, Botticelli A, Novello S, Ciliberto G, Cortesi E, Facciolo F, Cappuzzo F, Santini D. Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials. *Crit Rev Oncol Hematol*. 2023 Dec;192:104190. doi: 10.1016/j.critrevonc.2023.104190. Epub 2023 Oct 21. PMID: 37871779.

Manglaviti S, Bini M, Apollonio G, Zecca E, Galli G, Sangaletti S, Labianca A, Sottotetti E, Brambilla M, Occhipinti M, Proto C, Prelaj A, Signorelli D, De Toma A, Viscardi G, Beninato T, Mazzeo L, Bottiglieri A, Leporati R, Fotia G, Ganzinelli M, Portararo P, Garassino MC, de Braud FGM, Lo Russo G, Torri V, Ferrara R. High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors. *Lung Cancer*. 2023 Dec;186:107417. doi: 10.1016/j.lungcan.2023.107417. Epub 2023 Oct 29. PMID: 37918061.

Brambilla, M., Beninato, T., Piemontese, A., Mazzeo, L., Pircher, C. C., Manglaviti, S., Ambrosini, P., Signorelli, D., Lorenzini, D., Prelaj, A., Ferrara, R., Proto, C., Lo Russo, G., Pizzutilo, E. G., Ganzinelli, M., Grande, I., Capone, I., Di Mauro, R. M., Conca, E., Dumitrascu, A. D., ... Occhipinti, M. (2023). Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations. *Clinical lung cancer*, S1525-7304(23)00149-3. Advance online publication. <https://doi.org/10.1016/j.clc.2023.08.004>

Vingiani, A., Agnelli, L., Duca, M., Lorenzini, D., Damian, S., Proto, C., Niger, M., Nichetti, F., Tamborini, E., Perrone, F., Piccolo, A., Manoukian, S., Azzollini, J., Brambilla, M., Colombo, E., Lopez, S., Vernieri, C., Marra, F., Conca, E., Busico, A., ... Pruneri, G. (2023). Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care. *JCO precision oncology*, 7, e2300067. <https://doi.org/10.1200/PO.23.00067>

Lo Russo, G., Prelaj, A., Dolezal, J., Beninato, T., Agnelli, L., Triulzi, T., Fabbri, A., Lorenzini, D., Ferrara, R., Brambilla, M., Occhipinti, M., Mazzeo, L., Provenzano, L., Spagnoletti, A., Viscardi, G., Sgambelluri, F., Brich, S., Miskovic, V., Pedrocchi, A. L. G., Trovo', F., ... Garassino, M. C. (2023). PEOPLE (NCT03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis. *Journal for immunotherapy of cancer*, 11(6), e006833. <https://doi.org/10.1136/jitc-2023-006833>

Proto, C., Manglaviti, S., Lo Russo, G., Musca, M., Galli, G., Imbimbo, M., Perrino, M., Cordua, N., Rulli, E., Ballatore, Z., Maso, A. D., Chella, A., Sbrana, A., Prelaj, A., Ferrara, R., Occhipinti, M., Brambilla, M., De Toma, A., Mazzeo, L., Beninato, T., ... Zucali, P. A. (2023). STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines. *Journal of thoracic oncology* : official publication of the International Association for the Study of Lung Cancer, 18(8), 1070–1081. <https://doi.org/10.1016/j.jtho.2023.04.009>

Prelaj, A., Galli, E. G., Miskovic, V., Pesenti, M., Viscardi, G., Pedica, B., Mazzeo, L., Bottiglieri, A., Provenzano, L., Spagnoletti, A., Marinacci, R., De Toma, A., Proto, C., Ferrara, R., Brambilla, M., Occhipinti, M., Manglaviti, S., Galli, G., Signorelli, D., Giani, C., ... Pedrocchi, A. L. G. (2023). Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients. *Frontiers in oncology*, 12, 1078822. <https://doi.org/10.3389/fonc.2022.1078822>

Lo Russo, G., Sgambelluri, F., Prelaj, A., Galli, F., Manglaviti, S., Bottiglieri, A., Di Mauro, R. M., Ferrara, R., Galli, G., Signorelli, D., De Toma, A., Occhipinti, M., Brambilla, M., Rulli, E., Triulzi, T., Torelli, T., Agnelli, L., Brich, S., Martinetti, A., Dumitrascu, A. D., ... Garassino, M. C. (2022). PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers. *ESMO open*, 7(6), 100645. <https://doi.org/10.1016/j.esmoop.2022.100645>

Galli, G., Corsetto, P. A., Proto, C., Lo Russo, G., Ganzinelli, M., Rulli, E., Legramandi, L., Morelli, D., Ferrara, R., Prelaj, A., Signorelli, D., De Toma, A., Brambilla, M., Occhipinti, M., Manglaviti, S., Boeri, M., Martinetti, A., Vingiani, A., Colombo, M. P., Rizzo, A. M., ... Garassino, M. C. (2022). Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer. *Clinical lung cancer*, 23(7), e489–e499. <https://doi.org/10.1016/j.clc.2022.07.010>

Brunelli, C., Zecca, E., Pigni, A., Bracchi, P., Caputo, M., Lo Dico, S., Fusetti, V., Tallarita, A., Bergamini, C., Brambilla, M., Raimondi, A., Niger, M., Provenzano, S., Sepe, P., Alfieri, S., Tinè, G., De Braud, F., & Caraceni, A. T. (2022). Outpatient palliative care referral system (PCRS) for patients with advanced cancer: an impact evaluation protocol. *BMJ open*, 12(10), e059410. <https://doi.org/10.1136/bmjopen-2021-059410>

Signorelli, D., Ghidotti, P., Proto, C., Brambilla, M., De Toma, A., Ferrara, R., Galli, G., Ganzinelli, M., Lorusso, G., Prelaj, A., Occhipinti, M., Viscardi, G., Capizzuto, V., Pontis, F., Petrarola, I., Ferretti, A. M., Colombo, M. P., Torri, V., Sozzi, G., Garassino, M. C., ... Fortunato, O. (2022). Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC. *Frontiers in immunology*, 13, 987639. <https://doi.org/10.3389/fimmu.2022.987639>

Zattarin, E., Manglaviti, S., Apollonio, G., Beninato, T., Mazzeo, L., Massa, G., Bottiglieri, A., Galli, E., De Toma, A., Occhipinti, M., Brambilla, M., Ferrara, R., Ganzinelli, M., Proto, C., Garassino, M. C., de Braud, F., Lo Russo, G., & Prelaj, A. (2022). Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. *Future oncology* (London, England), 18(23), 2593–2604. <https://doi.org/10.2217/fon-2021-1454>

Prelaj, A., Bottiglieri, A., Bhat, G., Washington, R., Calareso, G., Greco, G. F., Ferrara, R., Brambilla, M., De Toma, A., Occhipinti, M., Manglaviti, S., Soro, A., Ganzinelli, M., Lo Russo, G., & Proto, C. (2022). Case Report: Exceptional Response to Pozotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation. *Frontiers in oncology*, 12, 902967. <https://doi.org/10.3389/fonc.2022.902967>

De Giglio, A., Di Federico, A., Deiana, C., Ricciuti, B., Brambilla, M., & Metro, G. (2022). Advanced non-small-cell lung cancer: how to manage non-oncogene disease. *Drugs in context*, 11, 2022-2-4. <https://doi.org/10.7573/dic.2022-2-4>

Metro, G., De Giglio, A., Ricciuti, B., Siringo, M., Marinelli, D., Gelibter, A., Pecci, F., Berardi, R., Cantini, L., Di Federico, A., Andrini, E., Mosca, M., Lamberti, G., Brambilla, M., & Mountzios, G. (2022). Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease. *Drugs in context*, 11, 2022-3-9. <https://doi.org/10.7573/dic.2022-3-9>

Zanella, C., Leone, A. G., Zambelli, L., Bottiglieri, A., Canziani, L., Brambilla, M., Lo Russo, G., Platania, M., De Braud, F., & Occhipinti, M. (2022). Paraneoplastic neurological syndromes in patients affected by SCLC: a case series. *Tumori*, 3008916221079663. Advance online publication. <https://doi.org/10.1177/03008916221079663>

Prelaj, A., Boeri, M., Robuschi, A., Ferrara, R., Proto, C., Lo Russo, G., Galli, G., De Toma, A., Brambilla, M., Occhipinti, M., Manglaviti, S., Beninato, T., Bottiglieri, A., Massa, G., Zattarin, E., Gallucci, R., Galli, E. G., Ganzinelli, M., Sozzi, G., de Braud, F. G. M., ... Trovo', F. (2022). Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy. *Cancers*, 14(2), 435. <https://doi.org/10.3390/cancers14020435>

Spagnoletti, A., Platania, M., Brambilla, M., Occhipinti, M., Canziani, L., Cabras, A., Provenzano, L., Leone, A. G., Ambrosini, P., & Prelaj, A. (2022). Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease. *Tumori*, 3008916211067565. Advance online publication. <https://doi.org/10.1177/03008916211067565>

S. Manglaviti, M. Brambilla, D. Signorelli, R. Ferrara, G. Lo Russo, C. Proto, G. Galli, A. De Toma, M. Occhipinti, G. Viscardi, T. Beninato, E. Zattarin, M. Bini, R. Lobefaro, G. Massa, A. Bottiglieri, G. Apollonio, E. Sottotetti, R.M. Di Mauro, B. Trevisan, et al, A. Prelaj. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology. *Clinical lung cancer*, 2021, Jul. S1525-7304(21)00180-7. Advance online publication. <https://doi.org/10.1016/j.clcc.2021.06.013>

F. Corti, S. Lonardi, R. Intini, M. Salati, E. Fenocchio, C. Belli, B. Borelli, M. Brambilla, A.A. Prete, V. Quarà, M. Antista, M. Fassan, F. Morano, A. Spallanzani, M. Ambrosini, G. Curigliano, F. de Braud, V. Zagonel, G. Fucà, & F. Pietrantonio. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. *European journal of cancer (Oxford, England : 1990)*. 2021, Jun. 150, 155–167. <https://doi.org/10.1016/j.ejca.2021.03.043>

M. Occhipinti, M. Brambilla, G. Galli, S. Manglaviti, M. Giammaruco, A. Prelaj, R. Ferrara, A. De Toma, C. Proto, T. Beninato, E. Zattarin, G. Lo Russo, A.J. Gelibter, M. Simmaco, R. Preissner, M.C. Garassino, F. De Braud, & P. Marchetti. Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. *Journal of personalized medicine*. 2021, May. 11(5), 424. <https://doi.org/10.3390/jpm11050424>  
A. Prelaj, A. Bottiglieri, C. Proto, G. Lo Russo, D. Signorelli, R. Ferrara, G. Galli, A. De Toma, G. Viscardi, M. Brambilla, R. Lobefaro, F. Nichetti, S. Manglaviti, M. Occhipinti, A. Labianca, M. Ganzinelli, R. Gallucci, N. Zilembo, G. F. Greco, V. Torri, et al, M.C. Garassino. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. *European journal of cancer (Oxford, England : 1990)*. 2021, May. 149, 235–248. <https://doi.org/10.1016/j.ejca.2021.02.038>

R. Lobefaro, G. Viscardi, R. Di Liello, G. Massa, M.L. Iacovino, F. Sparano, C.M. Della Corte, R. Ferrara, D. Signorelli, C. Proto, A. Prelaj, G. Galli, A. De Toma, M. Brambilla, M. Ganzinelli, B. Trevisan, F. Ciardiello, F. De Braud, F. Morgillo, M.C. Garassino, G. Lo Russo. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. *Lung Cancer*. 2021, Jan. Volume 152, Pages 165-173, ISSN 0169-5002, <https://doi.org/10.1016/j.lungcan.2020.12.027>.

M. Brambilla, G. Lo Russo, R. Ferrara, S. Manglaviti, M.C. Garassino, M. Occhipinti. Is hyperprogressive disease a specific phenomenon of immunotherapy? *Explor Target Antitumor Ther*. 2020, Dec. 1:427-33. <https://doi.org/10.37349/etat.2020.00027>

G. Viscardi, D. Di Natale, M. Fasano, M. Brambilla, R. Lobefaro, A. De Toma, G. Galli. Circulating biomarkers in malignant pleural mesothelioma. *Explor Target Antitumor Ther*. 2020, Dec. 1:434-51. <https://doi.org/10.37349/etat.2020.00028>

- R. Lobefaro, E. Zattarin, F. Nichetti, M. Prisciandaro, F. Ligorio, M. Brambilla, P. Sepe, F. Corti, G. Peverelli, A. Ottini, T. Beninato, L. Mazzeo, C.G. Rea, G. Mariani, F. de Braud, G.V. Bianchi, C. Vernieri, G. Capri. Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis. *Ther Adv Med Oncol.* **2020**, Dec . 7;12:1758835920970081. doi: 10.1177/1758835920970081. PMID: 33335565; PMCID: PMC7724266
- M. Niger, M. Prisciandaro, M. Antista, M.A.T. Monica, L. Cattaneo, N. Prinzi, S. Manglaviti, F. Nichetti, M. Brambilla, M. Torchio, F. Corti, S. Pusceddu, J. Coppa, V. Mazzaferro, F. de Braud, M. Di Bartolomeo. One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches. *World J Gastrointest Oncol.* **2020**, Aug 15;12(8):833-849. doi: 10.4251/wjgo.v12.i8.833. PMID: 32879662; PMCID: PMC7443847.
- A. Prelaj, C. Proto, G. Lo Russo, D. Signorelli, R. Ferrara, M. Mensah, G. Galli, A. De Toma, G. Viscardi, M. Brambilla, R. Lobefaro, B. Trevisan, F. Trovò, V. Torri, G. Sozzi, M.C. Garassino, M. Boeri. Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. *Transl Lung Cancer Res.* **2020**, Jun;9(3):617-628. doi: 10.21037/tlcr-20-231. PMID: 32676324; PMCID: PMC7354114.
- F. Corti, M. Brambilla, S. Manglaviti, L. Di Vico, M.N. Pisanu, C. Facchinetti, K.F. Dotti, R. Lanocita, A. Marchianò, F. de Braud, L.A.M. Ferrari. Comparison of outcomes of central venous catheters in patients with solid and hematologic neoplasms: an Italian real-world analysis. *Tumori*, **2020**, Jun 12:300891620931172. doi: 10.1177/0300891620931172. Epub ahead of print. PMID: 32529962.
- G. Galli, A. Trama, L. Abate-Daga, M. Brambilla, M.C. Garassino, A. Fabbri. Accuracy of pathologic diagnosis for thymic epithelial tumors: a brief report from an Italian reference Center. *Lung Cancer*, **2020**, May. Volume 146, August 2020, Pages 66-69
- C. Vernieri, M. Prisciandaro, F. Nichetti, R. Lobefaro, G. Peverelli, F. Ligorio, E. Zattarin, M.S. Cona, P. Sepe, F. Corti, S. Manglaviti, M. Brambilla, B. Re, C. Maggi, A. Belfiore, G. Pruneri, L. Celio, G. Mariani, G.V. Bianchi, L. Rivoltini, G. Capri, F. de Braud. Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. *Cancers*, Volume 12, Issue 3, **2020**, March. Article number 617
- A. Prelaj, R. Ferrara, S.E. Rebuzzi, C. Proto, D. Signorelli, G. Galli, A. De Toma, G. Randon, F. Pagani, G. Viscardi, M. Brambilla, B. Trevisan, M. Ganzinelli, A. Martinetti, R. Gallucci, R.M. Di Mauro, G. Molino, N. Zilembo, V. Torri, F. de Braud, M.C. Garassino, G. Lo Russo. EPSiLoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer A Validation Cohort. *Cancers.* **2019**, 11, 1954; doi.org/10.3390/cancers11121954
- B. Ricciuti, G.C. Leonardi, M. Brambilla. Emerging Biomarkers in the Era of Personalized Cancer Medicine. *Disease Markers*, vol. **2019**, Article ID 5907238, 2 pages, 2019. doi.org/10.1155/2019/5907238.
- C. Vernieri, M. Milano, M. Brambilla, A. Mennitto, C. Maggi, M.S. Cona, M. Prisciandaro, C. Fabbroni, L. Celio, G. Mariani, G. Capri, G.V. Bianchi, F. de Braud. Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: current knowledge, new research directions and therapeutic perspectives. *Critical Reviews in Oncology/Hematology.* **2019**, Jul;139:53-66; doi.org/10.1016/j.critrevonc.2019.05.001



- B. Ricciuti, C. Genova, M. Bassanelli, A. De Giglio, M. Brambilla, G. Metro, S. Baglivo, M.G. Dal Bello, A. Ceribelli, F. Grossi, R. Chiari. Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression. *Clin Lung Cancer*. **2019** May; *20*(3):178-185.e2. doi.org/10.1016/j.clcc.2019.02.001. Epub 2019 Feb 27.
- C. Vernieri, M. Prisciandaro, M. Brambilla, C. Fabbroni, A. Mennitto, E. Farè, G. Capri, L. Celio, G.V. Bianchi, M. Milano, C. Maggi, M.S. Cona, G. Mariani, S. Cresta, F. De Braud. Single-agent gemcitabine versus carboplatin-gemcitabine in advanced breast cancer: a retrospective comparison of efficacy and safety profiles. *Clin Breast Cancer*. **2019** Apr; *19*(2):e306-e318; doi.org/10.1016/j.clbc.2018.12.004
- B. Ricciuti, C. Genova, A. De Giglio, M. Bassanelli, M.G. Dal Bello, G. Metro, M. Brambilla, S. Baglivo, F. Grossi, R. Chiari. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. *J Cancer Res Clin Oncol*. **2019** Feb; *145*(2):479-485. doi.org/10.1007/s00432-018-2805-3. Epub 2018 Dec 1.
- B. Ricciuti, M. Brambilla, A. Cortellini, A. De Giglio, C. Ficorella, A. Sidoni, G. Bellezza, L. Crinò, V. Ludovini, S. Baglivo, G. Metro, R. Chiari. Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. *Clin Transl Oncol*. **2019** Jul; doi.org/10.1007/s12094-019-02175-y
- A. De Giglio, R. Porreca, M. Brambilla, G. Metro, E. Prosperi, G. Bellezza, M. Pirro, R. Chiari, B. Ricciuti. Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does Oncogene addiction matter? *Thrombosis Research*. **2018** Mar, *163*, 51; doi.org/10.1016/j.thromres.2017.12.004
- Ricciuti B, Baglivo S, Ludovini V, Sidoni A, Metro G, Brambilla M, Siggillino A, Reda MS, Rebonato A, Maiettini D, Chiari R. Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations. *Lung Cancer*. **2018** Jun; *120*:70-74. doi: 10.1016/j.lungcan.2018.04.002. Epub 2018 Apr 3. PMID: 29748019.
- B. Ricciuti, G. Metro, M. Brambilla, V. Ludovini, S. Baglivo, A. Siggillino, E. Prosperi, R. Chiari. Acquired resistance to afatinib due to T790M-positive squamous progression in EGFR mutant adenosquamous lung carcinoma. *Journal of Thoracic Oncology*. **2018** Jan, *13*(1),e9; doi.org/10.1016/j.jtho.2017.08.025
- B. Ricciuti, M. Brambilla, G. Metro, S. Baglivo, R. Matocci, M. Pirro, R. Chiari. Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. *Med Oncol*. **2017** Jun, *34*(6),105.
- B. Ricciuti, M. Brambilla, A. De Giglio, G. Metro, R. Porreca, R. Chiari, L. Paglialunga. Therapeutic approach to brain metastasis in high-grade neuroendocrine carcinomas of the lung: where do we stand? *J Radiat Oncol*. **2017** Feb, *6*, 11-19. doi.org/10.1007/s13566-017-0293-8
- G. Metro, B. Ricciuti, M. Brambilla, S. Baglivo, I. Soli, E. Minenza, GC. Leonardi, A. D'arpino, D. Colabrese, M. Tazza, D. Zicari, V. Minotti, R. Chiari. The safety of nivolumab for the treatment of advanced non small cell lung cancer. *Expert Opin Drug Saf*. **2017** Jan; *16*(1),101; doi.org/10.1080/14740338.2017.1267725
- B. Ricciuti, GC. Leonardi, N. Ravaoli, A. De Giglio, M. Brambilla, E. Prosperi, F. Ribacchi, ML. Meacci, L. Crinò, D. Maiettini, R. Chiari, G. Metro. Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient. *J Breast Cancer*. **2016** Sep, *19*(3), 324; http://dx.doi.org/10.4048/jbc.2016.19.3.324

Il sottoscritto MARTA BRAMBILLA, ai sensi di quanto previsto dagli artt. 19, 46 e 47 del D.P.R. 445/2000, consapevole delle conseguenze derivanti in caso di rilascio di dichiarazioni false, dichiara sotto la propria responsabilità che tutte le eventuali fotocopie allegate alla domanda di partecipazione al pubblico concorso, sono conformi all'originale in suo possesso e che ogni dichiarazione resa risponde a verità.

**In compliance with the GDPR and Italian Legislative Decree no. 196 dated 30/06/2003, I hereby authorize the recipient of this document to use and process my personal details for the purpose of recruiting and selecting staff and I confirm to be informed of my rights in accordance to art. 7 of the above mentioned Decree.**

Milano, 02/07/2024